Biomind Labs Inc. (BMNDF)
USD 0.7
(150.27%)
USD 0.7
(150.27%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 994.18 Thousand USD | -66.12% |
| 2022 | 2.93 Million USD | -14.38% |
| 2021 | 3.42 Million USD | 1679.42% |
| 2020 | 192.62 Thousand USD | -35.91% |
| 2019 | 300.55 Thousand USD | -84.81% |
| 2018 | 1.97 Million USD | -21.25% |
| 2017 | 2.51 Million USD | 117.88% |
| 2016 | 1.15 Million USD | -42.26% |
| 2015 | 1.99 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 107.95 Thousand USD | 13.71% |
| 2024 Q2 | 106.29 Thousand USD | -1.52% |
| 2023 Q2 | 359.47 Thousand USD | -12.52% |
| 2023 Q3 | 128.63 Thousand USD | -64.22% |
| 2023 Q4 | 94.94 Thousand USD | -26.19% |
| 2023 Q1 | 410.92 Thousand USD | -21.76% |
| 2023 FY | 994.18 Thousand USD | -66.12% |
| 2022 Q1 | 723.92 Thousand USD | -38.73% |
| 2022 FY | 2.93 Million USD | -14.38% |
| 2022 Q4 | 525.19 Thousand USD | -41.75% |
| 2022 Q3 | 901.62 Thousand USD | 15.57% |
| 2022 Q2 | 780.16 Thousand USD | 7.77% |
| 2021 Q1 | 296.56 Thousand USD | 0.0% |
| 2021 Q4 | 1.18 Million USD | -29.29% |
| 2021 Q2 | 274.65 Thousand USD | -7.39% |
| 2021 Q3 | 1.67 Million USD | 508.37% |
| 2021 FY | 3.42 Million USD | 1679.42% |
| 2020 Q1 | 49.45 Thousand USD | 0.0% |
| 2020 FY | 192.62 Thousand USD | -35.91% |
| 2019 FY | 300.55 Thousand USD | -84.81% |
| 2018 FY | 1.97 Million USD | -21.25% |
| 2017 FY | 2.51 Million USD | 117.88% |
| 2016 FY | 1.15 Million USD | -42.26% |
| 2015 FY | 1.99 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 25.553% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 80.282% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 96.636% |
| Nascent Biotech, Inc. | 2.22 Million USD | 55.415% |
| Rebus Holdings, Inc. | 664 Thousand USD | -49.726% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 97.331% |
| Qrons Inc. | 643.67 Thousand USD | -54.454% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -155.202% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 98.269% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -139.286% |
| Skye Bioscience, Inc. | 13.54 Million USD | 92.662% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.854% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 79.784% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -279.856% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.839% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 65.909% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 33.805% |
| Mesoblast Limited | 5.9 Million USD | 83.155% |
| Marizyme, Inc. | 19.23 Million USD | 94.833% |
| Genus plc | 147.7 Million USD | 99.327% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 88.676% |
| Pharming Group N.V. | 225.49 Million USD | 99.559% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 51.473% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 25.893% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 88.078% |
| ContraFect Corporation | 56.88 Million USD | 98.252% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 77.449% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 32.769% |
| IMV Inc. | 37.7 Million USD | 97.364% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 64.371% |
| MultiCell Technologies, Inc. | 567.42 USD | -175110.955% |
| ONE Bio Corp. | 6.44 Million USD | 84.572% |
| Accustem Sciences Inc. | 3.74 Million USD | 73.463% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.843% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -86.89% |
| Q BioMed Inc. | 3.43 Million USD | 71.071% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 95.977% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 62.163% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.999% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 43.502% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 85.201% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 46.675% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 4076.728% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 93.79% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 45.824% |
| GB Sciences, Inc. | 1.42 Million USD | 30.012% |
| Alpha Cognition Inc. | 9.7 Million USD | 89.757% |
| HST Global, Inc. | 140.9 Thousand USD | -605.559% |
| CSL Limited | 3.44 Billion USD | 99.971% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 11.621% |
| Halberd Corporation | 74.84 Thousand USD | -1228.374% |
| Enzolytics Inc. | 2.17 Million USD | 54.385% |
| Agentix Corp. | 1.37 Million USD | 27.525% |
| Resverlogix Corp. | 12.71 Million USD | 92.179% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 72.767% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.935% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 4.772% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 58.661% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 37.051% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 70.802% |
| AVAX Technologies, Inc. | 7.31 Million USD | 86.4% |
| Zenith Capital Corp. | 8.94 Million USD | 88.883% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.88% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -5606.802% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 59.509% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -479.668% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 48.244% |
| Kadimastem Ltd | 2.41 Million USD | 58.75% |
| Helix BioMedix, Inc. | 1.97 Million USD | 49.586% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 90.851% |
| BioStem Technologies, Inc. | 22.97 Million USD | 95.673% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -447.804% |
| LadRx Corporation | 3.81 Million USD | 73.918% |
| Cell Source, Inc. | 4.32 Million USD | 77.015% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -7.653% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -7.653% |
| NovAccess Global Inc. | 2.46 Million USD | 59.697% |
| Affymax, Inc. | 39.38 Million USD | 97.476% |
| Itoco Inc. | 919.14 Thousand USD | -8.164% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 76.544% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 11.154% |
| Mobile Lads Corp. | 554.54 Thousand USD | -79.279% |
| CytoDyn Inc. | 18.05 Million USD | 94.495% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -3850.026% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -351.741% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 29.977% |
| SYBLEU INC | 160.87 Thousand USD | -517.98% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 45.264% |
| International Stem Cell Corporation | 5.27 Million USD | 81.139% |
| Bioxytran, Inc. | 3.82 Million USD | 73.975% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -1788.572% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -4787.096% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 97.259% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 38.555% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -35.109% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 68.043% |
| Neutra Corp. | 243.82 Thousand USD | -307.751% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 94.305% |
| PureTech Health plc | 144.59 Million USD | 99.312% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 95.148% |
| IXICO plc | 4.7 Million USD | 78.879% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 88.699% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.156% |
| CSL Limited | 3.89 Billion USD | 99.974% |
| Cellectis S.A. | 97.32 Million USD | 98.978% |